{"id":35754,"date":"2015-05-07T07:13:21","date_gmt":"2015-05-07T11:13:21","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35754"},"modified":"2015-05-07T07:13:21","modified_gmt":"2015-05-07T11:13:21","slug":"gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754","title":{"rendered":"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Gilead Sciences, Inc. (NASDAQ:GILD)<\/strong> has acquired the private company EpiTherapeuticsApS in a deal worth $65 million. The deal gives Gilead a foothold in the field of epigenetics.<\/p>\n<p style=\"text-align: justify;\">The Denmark-based EpiTherapeutics develops cancer therapy and focuses on enzymes involved in the regulation of transcription in cancer. Gilead already has two drugs for hepatitis C, Harvoni and Sovaldi. The two drugs have generated sales of about $4.45 billion for Gilead in 1Q2015.<\/p>\n<p style=\"text-align: justify;\">Sovaldi and Harvoni are two of the most successful launches ever. The drugs have fewer side effects and high price tags. The drugs face increasing competition from new hepatitis C treatments like Viekira Pak.<\/p>\n<p style=\"text-align: justify;\">The deal adds to Gilead\u2019s drug pipeline with preclinical, firs in class small molecule inhibitors of enzymes involved in regulating gene transcription in cancer. The enzymes constitute a therapy class that represents a strategic fit with the existing research portfolio.<\/p>\n<p style=\"text-align: justify;\">EpiTherapeutics has not revealed much about its compounds. He company\u2019s site says that the pipeline building efforts are based knowledge within histone demethylases and methyltransferases as well as efforts to identify small molecule inhibitors of key enzymes within the family targeting unmet medical needs.<\/p>\n<p style=\"text-align: justify;\">Gilead has eight compounds under development for 11 hematology and oncology indications. 2 of the compounds have advanced to Phase III.<\/p>\n<p style=\"text-align: justify;\">EpiTherapeutics is studying its lead preclinical compounds for the treatment of unspecified cancers. EpiTHerapeutics\u2019 therapies are based on research by Professor KristianHelin and his research team at Biotech Research &amp; Innovation Centre at te University of Copenhagen.<\/p>\n<p style=\"text-align: justify;\">EpiTherapeutics was launched in 2008 with initial financing that later grew to $ 2.3 million and included investment by the largest Venture Capital seed fund in Denmark, the SEED Capital. Since then EpiTherapeutics has gotten investment from VC arms of several biopharma giants like Lundbeckfond Emerge, Astellas Venture Management and Merck KGaA\u2019s MS Ventures.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead Sciences, Inc. (NASDAQ:GILD) has acquired the private company EpiTherapeuticsApS in a deal worth $65 million. The deal gives Gilead a foothold in the field [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":19322,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[1978,1522],"stock_ticker":[],"class_list":["post-35754","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-gilead-sciences-inc-nasdaqgild","tag-nasdaqgild","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences, Inc. (NASDAQ:GILD) has acquired the private company EpiTherapeuticsApS in a deal worth $65 million. The deal gives Gilead a foothold in the field [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-07T11:13:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million\",\"datePublished\":\"2015-05-07T11:13:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754\"},\"wordCount\":306,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg\",\"keywords\":[\"Gilead Sciences Inc (NASDAQ:GILD)\",\"NASDAQ:GILD\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754\",\"name\":\"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg\",\"datePublished\":\"2015-05-07T11:13:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg\",\"width\":1024,\"height\":380},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754","og_locale":"en_US","og_type":"article","og_title":"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million - Wall Street PR","og_description":"Gilead Sciences, Inc. (NASDAQ:GILD) has acquired the private company EpiTherapeuticsApS in a deal worth $65 million. The deal gives Gilead a foothold in the field [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-05-07T11:13:21+00:00","og_image":[{"width":1024,"height":380,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million","datePublished":"2015-05-07T11:13:21+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754"},"wordCount":306,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg","keywords":["Gilead Sciences Inc (NASDAQ:GILD)","NASDAQ:GILD"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754","url":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754","name":"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg","datePublished":"2015-05-07T11:13:21+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/gilead-sciences.jpg","width":1024,"height":380},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/gilead-sciences-inc-nasdaqgild-acquires-epiterapeutics-for-65-million-35754#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35754"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35754\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/19322"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35754"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}